Interestingly, FDA-approved drugs that target several of these pathways such as GPCRs, integrins, and Src already exist [216,217,218,219,220,221,222] and could be re-purposed for use in YAP/TAZ-dependent cancers. This evidence concerns the gene SRC and cancer.